Clofarabine

Drug Profile

Clofarabine

Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Southern Research Institute
  • Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Corporation; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi Genzyme; Sanofi Oncology; University of Michigan Comprehensive Cancer Center; University of Utah; Yale University
  • Class Antineoplastics; Furans; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia
  • Phase II Histiocytosis
  • Phase I/II Haematological malignancies
  • Preregistration Submission Withdrawal Acute myeloid leukaemia
  • Discontinued B cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours

Most Recent Events

  • 25 May 2017 Genzyme terminates a phase I/II trial for Myelodysplastic syndromes and Chronic myelomonocytic leukaemia (Second-line therapy or greater) as data analysis revealed sufficient data for safety and efficacy in USA (PO) (NCT00708721)
  • 28 Apr 2017 Discontinued - Phase-I/II for Chronic myelomonocytic leukaemia (Second-line therapy or greater) in USA (PO) (Sanofi pipeline, June 2017)
  • 26 Mar 2017 Massachusettes General Hospital terminates a phase I/II trial in Non-Hodgkin lymphoma (Second-line therapy of greater) in USA due to discontinuation of drug formulation by Genzyme (NCT00644189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top